Search

Prasugrel

R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. … FDA approved in 2009.

Polymyxin B

Polymyxin B was discovered in the 1940s[A176429]. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes[A176426].

Mycophenolic acid

[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until … [A249175] This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency.

Naxitamab

[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neuroblastoma - it is widely … Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.

Tafasitamab

[L15307] It must be used in combination with [lenalidomide], as this combination results in greater efficacy as compared to either agent alone.[L15292] … [L15292,A191829] The CD19 surface protein is highly expressed on the surface of B-cells, where it appears to play a role in enhancing B-cell receptor signaling.

Glycopyrronium

[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers. … [A233565] Glycopyrronium was originally granted FDA approval on 11 August 1961.[L33090]

Ferrous cysteine glycinate

Pomalidomide

Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

Fludrocortisone

Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.

Erythropoietin

Epoetin alfa (Epoge) was developed by Amgen Inc. in 1983 as the first rhEPO commercialized in the United States, followed by other alfa and beta formulations. … Erythropoietin (EPO) is a growth factor produced in the kidneys that stimulates the production of red blood cells.